SRDX - SurModics - Biotech IPO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SRDX - SurModics - Biotech IPO

SRDX 26.95

-1.6%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lance Bredvold	11/14/2021 5:49:32 PM
	of 84

I've liked the way Gary Maharaj speaks, clearly and without exaggeration. The company has always made money but for the first time now, they've decided to breakout of the conservative pattern they've established and predict a loss for next year due to beginning to market their own products. Hired 8 sales people and predict huge market potential. And because they've always been so conservative in predictions, I believe them. Clearly it's disappointing that Surveil has been delayed, but management knew that when they decided to stop partnering products with the large pharma's and device companies and go it alone. Again, I am convinced they know what they are doing and would not try such a bold move without good reason. Still the market seems to be discouraged by the sudden predicted losses (and my own suspicion is that they decided once again not to count chickens before hatch so that any surprise is apt to be positive) and I'm anxious for the price to drop still more so I can buy more. I think my last purchase was on puts I'd sold for a $45 strike--yes, there it was at $45 less $7.10 put premium on 5/13/20. I might try that again now while so many seem discouraged. The question about cash position at yearend 2022 if ABT pays the possible milestone or if not, also was reassuring to me--no debt nor any need for more debt--and worst case, perhaps a borrowing from their $30mm line of credit--they did borrow $10 mm recently for the purchase of that company with a venous thrombectomy product named ReVene. Even that is a bold move for this management team and I'm confident was carefully thought out. I've sold a few at higher prices, bought at lower prices, but with no dividend and plenty of volatility, that is pretty much the only way I'm going to make money on SRDX--but it's an excellent investment none the less as long as I keep doing that. Best, L.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next